1194 related articles for article (PubMed ID: 30139211)
1. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
[TBL] [Abstract][Full Text] [Related]
2. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
Chu CM
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
[TBL] [Abstract][Full Text] [Related]
3. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
Choi GH; Kim GA; Choi J; Han S; Lim YS
Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
[TBL] [Abstract][Full Text] [Related]
4. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection.
Tan Z; Li M; Kuang X; Tang Y; Fan Y; Deng G; Wang Y; He D
J Clin Virol; 2014 Apr; 59(4):228-34. PubMed ID: 24529415
[TBL] [Abstract][Full Text] [Related]
7. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection.
Dikici B; Bosnak M; Ucmak H; Dagli A; Ece A; Haspolat K
J Gastroenterol Hepatol; 2003 Feb; 18(2):218-22. PubMed ID: 12542609
[TBL] [Abstract][Full Text] [Related]
8. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
9. Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing.
Croagh CM; Bell SJ; Locarnini S; Desmond PV
Intern Med J; 2012 Feb; 42(2):170-5. PubMed ID: 21241443
[TBL] [Abstract][Full Text] [Related]
10. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
11. What can we learn from hepatitis B virus clinical cohorts?
Lin CL; Tseng TC; Kao JH
Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
[TBL] [Abstract][Full Text] [Related]
12. A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies.
Xiang Y; Chen P; Xia JR; Zhang LP
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252163
[TBL] [Abstract][Full Text] [Related]
13. The prognosis and management of inactive HBV carriers.
Invernizzi F; Viganò M; Grossi G; Lampertico P
Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
[TBL] [Abstract][Full Text] [Related]
14. HBeAg/anti-HBe, alanine aminotransferase and HBV DNA levels in HBsAg positive chronic carriers.
Rabbi FJ; Rezwan MK; Shirin T
Bangladesh Med Res Counc Bull; 2008 Aug; 34(2):39-43. PubMed ID: 19119537
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
[TBL] [Abstract][Full Text] [Related]
16. Management of chronic hepatitis B.
Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.
Wong RJ; Nguyen MT; Trinh HN; Chan C; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Torres S; Yang J; Liu B; Garcia RT; Bhuket T; Baden R; Levitt B; da Silveira E; Gish RG
J Viral Hepat; 2017 Dec; 24(12):1089-1097. PubMed ID: 28581644
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.
Feld JJ; Ayers M; El-Ashry D; Mazzulli T; Tellier R; Heathcote EJ
Hepatology; 2007 Oct; 46(4):1057-70. PubMed ID: 17654702
[TBL] [Abstract][Full Text] [Related]
19. Are serum quantitative hepatitis b surface antigen levels, liver histopathology and viral loads related in chronic hepatitis b-infected patients?
Balkan A; Namiduru M; Balkan Y; Mete AO; Karaoglan I; Bosnak VK
Saudi J Gastroenterol; 2016; 22(3):208-14. PubMed ID: 27184639
[TBL] [Abstract][Full Text] [Related]
20. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
